A Family of Phosphoinositide 3-kinases in Drosophila Identifies a New Mediator of Signal Transduction
Overview
Authors
Affiliations
Background: Mammalian phosphoinositide 3-kinases (PI 3-kinases) are involved in receptor-mediated signal transduction and have been implicated in processes such as transformation and mitogenesis through their role in elevating cellular phosphatidylinositol (3,4,5)-trisphosphate. Additionally, a PI 3-kinase activity which generates phosphatidylinositol 3-phosphate has been shown to be required for protein trafficking in yeast.
Results: We have identified a family of three distinct PI 3-kinases in Drosophila, using an approach based on the polymerase chain reaction to amplify a region corresponding to the conserved catalytic domain of PI 3-kinases. One of these family members, PI3K_92D, is closely related to the prototypical PI 3-kinase, p110 alpha; PI3K_59F is homologous to Vps34p, whereas the third, PI3K_68D, is a novel PI 3-kinase which is widely expressed throughout the Drosophila life cycle. The PI3K_68D cDNA encodes a protein of 210 kDa, which lacks sequences implicated in linking p110 PI 3-kinases to p85 adaptor proteins, but contains an amino-terminal proline-rich sequence, which could bind to SH3 domains, and a carboxy-terminal C2 domain. Biochemical analyses demonstrate that PI3K_68D has a novel substrate specificity in vitro, restricted to phosphatidylinositol and phosphatidylinositol 4-phosphate, and is unable to phosphorylate phosphatidylinositol (4,5)-bisphosphate, the implied in vivo substrate for p110.
Conclusions: A family of PI 3-kinases in Drosophila, including a novel class represented by PI3K_68D, is described. PI3K_68D has the potential to bind to signalling molecules containing SH3 domains, lacks p85-adaptor-binding sequences, has a Ca(2+)-independent phospholipid-binding domain and displays a restricted in vitro substrate specificity, so it could define a novel signal transduction pathway.
The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors.
Li P, Ma X, Gu X Front Cell Dev Biol. 2024; 12:1442193.
PMID: 39161590 PMC: 11330846. DOI: 10.3389/fcell.2024.1442193.
An Overview of Class II Phosphoinositide 3-Kinases.
Heng E, Maffucci T Curr Top Microbiol Immunol. 2022; 436:51-68.
PMID: 36243839 DOI: 10.1007/978-3-031-06566-8_2.
Phosphoinositide 3-Kinases as Potential Targets for Thrombosis Prevention.
Setiabakti N, Larsson P, Hamilton J Int J Mol Sci. 2022; 23(9).
PMID: 35563228 PMC: 9105564. DOI: 10.3390/ijms23094840.
Lebo D, Chirn A, Taylor J, Levan A, Doerre Torres V, Agreda E G3 (Bethesda). 2021; 11(2).
PMID: 33693600 PMC: 8022946. DOI: 10.1093/g3journal/jkaa066.
Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours.
Paton E, Turner J, Schlaepfer I J Oncol. 2020; 2020:1079827.
PMID: 32411231 PMC: 7199609. DOI: 10.1155/2020/1079827.